Bellerophon Therapeutics, Inc. Share Price
Equities
BLPH
US0787713009
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0554 USD | +0.73% | +1.84% | +49.73% |
04-25 | North American Morning Briefing : More Tech -2- | DJ |
04-11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
Sales 2021 | - | Sales 2022 | - | Capitalization | 8.59M 688M |
---|---|---|---|---|---|
Net income 2021 | -17M -1.36B | Net income 2022 | -19M -1.52B | EV / Sales 2021 | - |
Net cash position 2021 | 23.78M 1.9B | Net cash position 2022 | 6.72M 538M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.66
x | P/E ratio 2022 |
-0.43
x | Employees | 18 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.97% |
Latest transcript on Bellerophon Therapeutics, Inc.
1 day | +0.73% | ||
1 week | +1.84% | ||
Current month | -2.46% | ||
1 month | -2.46% | ||
3 months | -9.18% | ||
6 months | +53.89% | ||
Current year | +49.73% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Jalbert
CEO | Chief Executive Officer | 63 | - |
Martin Dekker
CTO | Chief Tech/Sci/R&D Officer | 51 | 28/01/15 |
Edwin L. Parsley
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Naseem Amin
CHM | Chairman | 62 | 28/06/15 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.0554 | +0.73% | 17,511 |
25/04/24 | 0.055 | +1.66% | 10,136 |
24/04/24 | 0.0541 | -7.68% | 47,040 |
23/04/24 | 0.0586 | +14.68% | 5,012 |
22/04/24 | 0.0511 | -6.07% | 2,320 |
Delayed Quote OTC Markets, April 26, 2024 at 07:10 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+49.73% | 678K | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BLPH Stock